Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 4
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD. Zanos P, et al. Among authors: highland jn. Pharmacol Rev. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Pharmacol Rev. 2018. PMID: 29945898 Free PMC article. Review.
Experimenters' sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor.
Georgiou P, Zanos P, Mou TM, An X, Gerhard DM, Dryanovski DI, Potter LE, Highland JN, Jenne CE, Stewart BW, Pultorak KJ, Yuan P, Powels CF, Lovett J, Pereira EFR, Clark SM, Tonelli LH, Moaddel R, Zarate CA Jr, Duman RS, Thompson SM, Gould TD. Georgiou P, et al. Among authors: highland jn. Nat Neurosci. 2022 Sep;25(9):1191-1200. doi: 10.1038/s41593-022-01146-x. Epub 2022 Aug 30. Nat Neurosci. 2022. PMID: 36042309 Free PMC article.
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.
Highland JN, Zanos P, Riggs LM, Georgiou P, Clark SM, Morris PJ, Moaddel R, Thomas CJ, Zarate CA Jr, Pereira EFR, Gould TD. Highland JN, et al. Pharmacol Rev. 2021 Apr;73(2):763-791. doi: 10.1124/pharmrev.120.000149. Pharmacol Rev. 2021. PMID: 33674359 Free PMC article. Review.
(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD. Zanos P, et al. Among authors: highland jn. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13. Proc Natl Acad Sci U S A. 2019. PMID: 30867285 Free PMC article.
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris PJ, Stewart BW, Thomas CJ, Thompson SM, Moaddel R, Gould TD. Zanos P, et al. Among authors: highland jn. Br J Pharmacol. 2019 Jul;176(14):2573-2592. doi: 10.1111/bph.14683. Epub 2019 May 13. Br J Pharmacol. 2019. PMID: 30941749 Free PMC article.
A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.
Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM. Zanos P, et al. Among authors: highland jn. eNeuro. 2017 Mar 7;4(1):ENEURO.0285-16.2017. doi: 10.1523/ENEURO.0285-16.2017. eCollection 2017 Jan-Feb. eNeuro. 2017. PMID: 28275719 Free PMC article.